H. Berna Beverloo

17.0k total citations · 3 hit papers
125 papers, 9.4k citations indexed

About

H. Berna Beverloo is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, H. Berna Beverloo has authored 125 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Hematology, 54 papers in Molecular Biology and 49 papers in Public Health, Environmental and Occupational Health. Recurrent topics in H. Berna Beverloo's work include Acute Myeloid Leukemia Research (51 papers), Acute Lymphoblastic Leukemia research (49 papers) and Chronic Myeloid Leukemia Treatments (31 papers). H. Berna Beverloo is often cited by papers focused on Acute Myeloid Leukemia Research (51 papers), Acute Lymphoblastic Leukemia research (49 papers) and Chronic Myeloid Leukemia Treatments (31 papers). H. Berna Beverloo collaborates with scholars based in Netherlands, United States and Germany. H. Berna Beverloo's co-authors include Ellen van Drunen, Bob Löwenberg, Peter J.M. Valk, Claudia Erpelinck-Verschueren, Rob Pieters, Ruud Delwel, Peter J. van der Spek, Roland Kanaar, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani and Jules P.P. Meijerink and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

H. Berna Beverloo

122 papers receiving 9.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia

2004 997 citations Peter J.M. Valk, Claudia Erpelinck-Verschueren et al. profile →
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

2009 595 citations Monique L. den Boer, H. Berna Beverloo et al. profile →
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

2022 159 citations Tim Grob, Adil S. A. Al Hinai et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H. Berna Beverloo Netherlands	50	5.3k	4.5k	2.3k	1.7k	1.2k	125	9.4k
Josef Vormoor Germany	35	3.2k 0.6×	2.7k 0.6×	1.2k 0.5×	3.5k 2.0×	1.2k 1.0×	117	7.8k
Jan Cools Belgium	55	3.0k 0.6×	2.8k 0.6×	1.6k 0.7×	1.8k 1.0×	693 0.6×	185	8.5k
John D. Crispino United States	52	5.0k 0.9×	3.2k 0.7×	906 0.4×	698 0.4×	678 0.6×	168	8.1k
D. Gary Gilliland United States	62	8.4k 1.6×	8.1k 1.8×	2.3k 1.0×	2.8k 1.6×	1.7k 1.4×	126	16.2k
Guy Sauvageau Canada	52	7.4k 1.4×	3.9k 0.9×	495 0.2×	1.7k 1.0×	1.0k 0.9×	210	10.3k
Brian J.P. Huntly United Kingdom	42	4.3k 0.8×	3.7k 0.8×	508 0.2×	1.1k 0.6×	890 0.8×	112	7.5k
Harry A. Drabkin United States	53	7.3k 1.4×	1.6k 0.4×	413 0.2×	2.8k 1.6×	1.7k 1.5×	167	10.7k
Catriona Jamieson United States	42	6.7k 1.2×	3.4k 0.8×	466 0.2×	4.1k 2.3×	1.8k 1.5×	187	12.2k
Markus Müschen United States	40	2.0k 0.4×	984 0.2×	722 0.3×	1.1k 0.6×	493 0.4×	165	4.3k
David Dombkowski United States	36	3.4k 0.6×	1.7k 0.4×	494 0.2×	1.9k 1.1×	810 0.7×	51	6.6k

Countries citing papers authored by H. Berna Beverloo

Since Specialization

Citations

This map shows the geographic impact of H. Berna Beverloo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Berna Beverloo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Berna Beverloo more than expected).

Fields of papers citing papers by H. Berna Beverloo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Berna Beverloo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Berna Beverloo. The network helps show where H. Berna Beverloo may publish in the future.

Co-authorship network of co-authors of H. Berna Beverloo

This figure shows the co-authorship network connecting the top 25 collaborators of H. Berna Beverloo. A scholar is included among the top collaborators of H. Berna Beverloo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Berna Beverloo. H. Berna Beverloo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Havermans, Marije, Roger Mulet‐Lazaro, Leonie Smeenk, et al.. (2025). MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia. Blood. 146(25). 3098–3105.

Pieters, Rob, Hester de Groot‐Kruseman, Marta Fiocco, et al.. (2023). Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups. Journal of Clinical Oncology. 41(25). 4130–4142. 25 indexed citations

Boeree, Aurélie, Edwin Sonneveld, Anthony V. Moorman, et al.. (2023). Targeted treatment options for paediatric B-cell precursor acute lymphoblastic leukaemia patients with constitutional or somatic chromosome 21 alterations. SHILAP Revista de lepidopterología. 3. 100140–100140. 2 indexed citations

Grob, Tim, Adil S. A. Al Hinai, Mathijs A. Sanders, et al.. (2022). Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 139(15). 2347–2354. 159 indexed citations breakdown →

Bruinink, Davine Hofste op, Rowan Kuiper, Mark van Duin, et al.. (2022). Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. Journal of Clinical Oncology. 40(27). 3132–3150. 16 indexed citations

Mulet‐Lazaro, Roger, Claudia Erpelinck-Verschueren, Marije Havermans, et al.. (2021). The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops. Nature Communications. 12(1). 5679–5679. 40 indexed citations

Bouwkamp, Christian G., Zaid Afawi, Aviva Fattal‐Valevski, et al.. (2018). ACO2 homozygous missense mutation associated with complicated hereditary spastic paraplegia. Neurology Genetics. 4(2). e223–e223. 22 indexed citations

Balgobind, Brian V., Iris H.I.M. Hollink, Susan T.C.J.M. Arentsen-Peters, et al.. (2011). Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica. 96(10). 1478–1487. 76 indexed citations

Calbó, Joaquim, Erwin van Montfort, Natalie Proost, et al.. (2011). A Functional Role for Tumor Cell Heterogeneity in a Mouse Model of Small Cell Lung Cancer. Cancer Cell. 19(2). 244–256. 258 indexed citations

10.

Deenik, Wendy, Jeroen J. W. M. Janssen, Bronno van der Holt, et al.. (2009). Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica. 95(6). 914–921. 19 indexed citations

11.

Grotel, Martine van, Jules P.P. Meijerink, Elisabeth R. van Wering, et al.. (2007). Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia. 22(1). 124–131. 91 indexed citations

12.

Sandberg, Yorick, Ka Lung Wu, Renate R. van den Bos, et al.. (2007). Clinically and genetically atypical T-cell prolymphocytic leukemia underlines the relevance of a multidisciplinary diagnostic approach. Haematologica. 92(3). e34–e36. 2 indexed citations

13.

Looijenga, Leendert H. J., Remko Hersmus, Ad Gillis, et al.. (2006). Genomic and Expression Profiling of Human Spermatocytic Seminomas: Primary Spermatocyte as Tumorigenic Precursor and DMRT1 as Candidate Chromosome 9 Gene. Cancer Research. 66(1). 290–302. 170 indexed citations

14.

Bergh, Anne R. M. von, Ellen van Drunen, Elisabeth R. van Wering, et al.. (2006). High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9. Genes Chromosomes and Cancer. 45(8). 731–739. 59 indexed citations

15.

Vlierberghe, Pieter Van, Martine van Grotel, H. Berna Beverloo, et al.. (2006). The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood. 108(10). 3520–3529. 123 indexed citations

16.

Burg, Mirjam van der, Tim Svenstrup Poulsen, Stephen P. Hunger, et al.. (2004). Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia. Leukemia. 18(5). 895–908. 45 indexed citations

17.

Niedernhofer, Laura J., Hanny Odijk, Magda Budzowska, et al.. (2004). The Structure-Specific Endonuclease Ercc1-Xpf Is Required To Resolve DNA Interstrand Cross-Link-Induced Double-Strand Breaks. Molecular and Cellular Biology. 24(13). 5776–5787. 407 indexed citations

18.

Beverloo, H. Berna, et al.. (2000). Mouse RAD54 Affects DNA Double-Strand Break Repair and Sister Chromatid Exchange. Molecular and Cellular Biology. 20(9). 3147–3156. 145 indexed citations

19.

Släter, R, et al.. (1999). T(7;12)(q36;p13) - A new translocation involving ETV6 associated with a poor prognosis in myeloid malignancies of very young children. Data Archiving and Networked Services (DANS). 1 indexed citations

20.

Beverloo, H. Berna, Annemarie van Schadewijk, J. Bonnet, et al.. (1992). Preparation and microscopic visualization of multicolor luminescent immunophosphors. Cytometry. 13(6). 561–570. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact